NCT00080015View on ClinicalTrials.gov

Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 12, 2004

Primary Completion Date

February 28, 2005

Study Completion Date

February 28, 2005

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Diflomotecan (BN80915)

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY